Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & Oncology [Yahoo! Finance]
Rigel Pharmaceuticals, Inc. (RIGL)
Last rigel pharmaceuticals, inc. earnings: 2/27 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.rigel.com
Company Research
Source: Yahoo! Finance
Rigel advances its strategic collaborations to further evaluate olutasidenib with the activation of a fifth study with MD Anderson and enrollment of the first patient in the CONNECT TarGeT-D study SOUTH SAN FRANCISCO, Calif. Nov. 17, 2025 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL), a commercial stage biotechnology company focused on hematologic disorders and cancer, today announced a peer-reviewed publication in the Journal of Hematology & Oncology of the final five-year data from the pivotal cohort of the Phase 2 registrational trial evaluating REZLIDHIA ® (olutasidenib) for the treatment of patients with relapsed or refractory (R/R) mutant isocitrate dehydrogenase-1 (m IDH1) acute myeloid leukemia (AML). REZLIDHIA is a potent, selective, oral, small-molecule inhibitor of m IDH1 that is approved for the treatment of R/R m IDH1 AML. The publication reports the final follow-up analysis of the registrational Phase 2 trial, with an additional two years of efficacy an
Show less
Read more
Impact Snapshot
Event Time:
RIGL
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RIGL alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RIGL alerts
High impacting Rigel Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
RIGL
News
- Rigel Pharmaceuticals (RIGL) is a Great Momentum Stock: Should You Buy? [Yahoo! Finance]Yahoo! Finance
- Rigel to Present at the Piper Sandler 37th Annual Healthcare ConferencePR Newswire
- Rigel Pharmaceuticals: Behind The Huge Rally [Seeking Alpha]Seeking Alpha
- Rigel Announces Publication of Final 5-year Data on REZLIDHIA® (olutasidenib) in Patients with R/R mIDH1 AML in the Journal of Hematology & OncologyPR Newswire
- Rigel to Present at the Jefferies Global Healthcare Conference in LondonPR Newswire
RIGL
Earnings
- 11/4/25 - Beat
RIGL
Sec Filings
- 11/14/25 - Form SCHEDULE
- 11/4/25 - Form 8-K
- 11/4/25 - Form 10-Q
- RIGL's page on the SEC website